TIANJIN, China, July 10, 2026 /PRNewswire/ -- Weichai Power (HKG:2338) announced that its independently developed WP15 hydrogen direct‑injection engine for heavy-duty vehicles has successfully passed the full China VI vehicle emission certification tests on July 3 at the CATARC Automotive Test Center (Tianjin) Co., Ltd. The achievement makes it the first heavy‑duty hydrogen internal combustion engine in both China and the world to comply with the country's stringent China VI emission standard.

The certification was conducted under the complete operating cycle required by China's national heavy-duty engine emission standards. Testing covered a full range of operation condition, including cold start, low‑speed idling, high‑speed full‑load, and transient variable load changes, verifying the engine's emission performance, reliability and stability in real‑world applications.

Designed for zero‑carbon heavy‑duty transportation, the WP15 adopts a hydrogen direct-injection, spark‑ignited architecture and delivers industry-leading performance. Featuring a 14.6-liter displacement, the engine produces up to 600 horsepower and 2,800 N•m of torque while achieving a maximum brake thermal efficiency of 46.8%, combining strong power, low consumption, and zero emissions with strong commercialization potential.

With over 90% component commonality with conventional engine platforms, the WP15 inherits proven advantages in load capacity, range, and environmental adaptability, reducing production, retrofitting, and maintenance costs. Furthermore, its higher tolerance for hydrogen purity also lowers end-user fuel costs and accelerates fossil fuel replacement. The engine is well-suited for long-haul trucks, mining dump trucks, port equipment, steel mill vehicles, and large hydrogen power generators, driving green upgrades across transportation and heavy equipment sectors.

With 80 years of history, Weichai has been at the forefront of hydrogen power innovation in China. Through sustained investment in research and development, the company has established an integrated innovation system spanning fundamental research, technology development, product engineering, testing and commercialization, achieving multiple breakthroughs in the key hydrogen engine technologies.

This certification represents a significant achievement in Weichai's deep commitment to independent innovation and green development. Looking ahead, the company will accelerate mass production, actively support national hydrogen demonstration projects, and continue delivering high‑performance, zero‑carbon powertrain solutions that advance industrial decarbonization and the sustainable growth of the hydrogen energy industry.

For more information about Weichai Power, please visit https://weichai.com/ and its pages on X https://x.com/WeichaiOfficial and Facebook https://www.facebook.com/WeichaiGroup.

Tashan Technology, the first global haptic simulation partner of NVIDIA Corporation (NVDA.US), recently completed a B-round financing worth several hundred million RMB.

Investors in this round included JOYSON ELEC (00699.HK), Taiping Innovation, AUX, PENGLING (300375.SZ), Lavender Hill Capital Partners (LHCP), and other industry investors. Existing shareholders DOWSTONE TECH (300409.SZ) and BeFor Capital also made additional investments.

Founded in 2017, Tashan Technology was jointly established by core teams from Tsinghua University, the University of Manchester and other global senior R&D teams. In 2025, the company completed its A3-A5 financing rounds, attracting participation from 15 leading cross-sector investors.
~

AASTOCKS Financial News
Website: www.aastocks.com

Meta Platforms, Inc. (META.US) plans to begin production of its AI chip codenamed "Iris" starting in September, Reuters, citing an internal memo, reported. The chip is Meta's fourth-generation Meta Training and Inference Accelerator (MTIA).

Meta hopes to use the chip to enhance AI performance on its Facebook and Instagram social media platforms. The memo showed that testing of the chip took only six weeks and no major issues were identified.

The chip was designed by Meta based on its own requirements, with Broadcom Inc. (AVGO.US) providing design assistance, while manufacturing is handled by Taiwan Semiconductor Manufacturing Company Ltd. (TSM.US).

For Meta, the main purpose of developing in-house chips is to supplement existing GPU resources, reduce AI infrastructure costs, and lessen dependence on NVIDIA Corporation (NVDA.US) and Advanced Micro Devices, Inc. (AMD.US).
~

AASTOCKS Financial News
Website: www.aastocks.com

Samsung Electronics Chairman Lee Jae-yong is expected to meet NVIDIA Corporation (NVDA.US) CEO Jensen Huang in the US later this month, aiming to expand cooperation in semiconductor and AI investment plans, South Korean media reported.

Lee is reportedly arranging a meeting with Huang in Silicon Valley. The increasingly close cooperative relationship between Samsung and NVIDIA is expected to become a key topic.

Initial cooperation between the two sides mainly focused on Samsung's memory chips and NVIDIA's GPUs, but has now expanded into the foundry business. Samsung is producing Groq 3 language processors for NVIDIA under contract.
~

AASTOCKS Financial News
Website: www.aastocks.com

北京2026年7月9日 /美通社/ -- 近日，AI製藥領軍企業晶泰科技（2228.HK）與代謝疾病領域龍頭甘李藥業（603087.SH）聯合共建的「AI智肽遞送實驗室」（人工智能多肽藥物設計與遞送系統研發北京市重點實驗室），獲得「北京市重點實驗室」認定並正式揭牌。這是繼去年11月雙方建立戰略夥伴關係以來的又一重要合作進展，標誌著雙方在AI賦能多肽藥物研發的領域合作步入全面深化階段，也印證了晶泰科技AI多肽開發平台PepiX™在產業端的持續轉化與規模化應用潛力。

中國科學院院士、世界科學院院士馬光輝，加拿大皇家科學院院士Andrei K. Yudin，晶泰科技聯合創始人、首席創新官賴力鵬博士，甘李藥業創始人甘忠如博士，甘李藥業董事長兼CEO陳偉博士等專家及嘉賓出席揭牌儀式。

北京市重點實驗室是北京科技創新體系的重要組成部分，承載著集聚優秀創新人才、開展高水平研究、推動關鍵技術攻關的戰略任務。此次重點實驗室成功獲批，標誌著晶泰科技源頭創新實力與工程化落地能力再次獲得權威認可。同時，晶泰科技將依托這一高能級創新載體，與戰略合作方甘李藥業、科研夥伴中國科學院過程工程研究所深度協同，加速新一代多肽藥物的研發突破與臨床轉化。

當前，受益於GLP-1類藥物的爆發式增長，多肽藥物正迎來黃金發展期，研發方向加速向多靶點、口服化、長效化等新形態演進。然而，多肽分子在體內易降解、靶向遞送效率低，以及高端遞送載體及核心制備工藝長期被海外壟斷等挑戰制約了國內多肽新藥轉化。面對上述難題，晶泰科技與甘李藥業基於已有的堅實合作基礎，聯合共建 「AI 智肽遞送實驗室」，重點圍繞代謝性慢病領域開展研究，致力於構建 「分子設計-遞送開發-臨床轉化」 的全鏈條技術平台，加速推動本土多肽新藥的研發和臨床轉化進程。

該聯合實驗室主要圍繞三大方向開展技術攻關：一是打造AI驅動的「虛擬篩選+濕實驗驗證」一體化平台，推進代謝性慢病治療多肽分子的設計與成藥性優化；二是開發新型口服遞送系統，提升多肽藥物的胃腸道穩定性、跨膜轉運效率及生物利用度；三是探索超長效遞送與緩釋制劑技術，推動給藥向更長週期延展。

晶泰科技自主研發的AI多肽藥物開發平台PepiX™，融合精準AI設計、高通量濕實驗篩選與自動化合成三大能力，構建「干實驗設計+濕實驗驗證」的高效研發閉環，將傳統多肽研發週期從數年壓縮至數月。甘李藥業作為國內代謝疾病領域的龍頭企業，擁有深厚的產業積澱與臨床轉化實力，已構建起「多肽分子設計-遞送系統開發-代謝慢病轉化」的完整能力閉環，使實驗室能夠高效完成從靶點發現到產業化的全流程驗證。雙方強強聯合，有望打通「研發-臨床-產業化」完整鏈路，加速更安全、更高效的新一代多肽藥物的臨床轉化進程，並在真實的藥物研發場景中進一步拓寬雙方的技術護城河。

目前，晶泰科技PepiX™平台已實現多賽道技術落地，正在重點佈局多款腦部遞送、眼部遞送及口服肽等高潛力多肽藥物的開發並取得多項標桿性成果。其中，PepiX™研發的食品級口服功能肽Tensotide已正式獲得美國Self-affirmed GRAS（一般認為安全）認證，可合法用於美國食品及膳食補充劑市場。依托此次獲批的「AI智肽遞送實驗室」，晶泰科技與甘李藥業將在前期成功合作的基礎上，進一步深化戰略協同，共同構建「政產學研用」深度融合的協同創新生態，加速原創多肽新藥從研發設計到產業化落地的全鏈條轉化進程，推動國產多肽創新藥物在代謝類慢病領域實現關鍵突破，為全球患者帶來更優的治療選擇。

甘李藥業董事長兼CEO陳偉表示：「實驗室由甘李藥業、晶泰科技、中科院過程工程研究所三方共同參與、優勢互補，形成了AI解題、基礎研究與產業拓展深度融合的創新模式，這正是中國生物藥從Fast Follow走向First-in-class所必需的生態融合。」

晶泰科技聯合創始人、首席創新官賴力鵬表示：「此次『AI智肽遞送實驗室』獲認定為北京市重點實驗室，標誌著晶泰科技與甘李藥業的戰略合作邁入新階段。我們期待以此實驗室為平台，充分發揮晶泰科技在AI多肽分子設計、自動化合成及高通量濕實驗篩選方面的全鏈條早期研發技術優勢，結合甘李藥業在代謝類多肽領域數十年的產業積累與卓越的臨床轉化能力，聯合攻堅長效修飾智能遞送的產業難題，推動更多具有差異化優勢的多肽新藥進入臨床。」

關於甘李藥業

甘李藥業股份有限公司（簡稱：甘李藥業，股票代碼：603087.SH）作為中國第一家掌握產業化生產重組胰島素類似物技術的高科技生物製藥企業，具備完整胰島素研發管線。

甘李藥業在中國胰島素第二次集中帶量採購中，胰島素類似物中選協議量居中選企業首位，國內市場基礎持續夯實。與此同時，公司國際化進程穩步推進，甘精胰島素注射液、賴脯胰島素注射液及門冬胰島素注射液均已獲得歐盟委員會（EC）上市批准，正穩步向全球代謝疾病領域核心參與者邁進。

立足中國，放眼全球，甘李藥業始終致力於為全球患者提供更高質量的藥品與服務。

關於晶泰科技

晶泰科技（「XtalPi Holdings Limited」，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為製藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。

SHENZHEN, China, July 9, 2026 /PRNewswire/ -- nubia, a highly personalized and lifestyle smartphone brand, announced the launch of nubia Neo 5 GT Special Edition, the latest addition to its Neo lineup built on the belief to bring pro-level gaming to everyone. Designed for young gamers and tech-savvy Gen Z users seeking premium gaming experience without compromise, the new device makes the sustained performance accessible to everyone through the AquaCore Cooling System - the first and only Liquid & Air Dual Active Cooling System in its class, alongside lightning-fast triggers, marathon battery life, an esports-level AI Game Space, and the exclusive AI Copilot Demi 2.0.

"At nubia, our brand DNA is built on relentless tech innovation and deep gamer insights, enabling us to continuously push gaming smartphones forward. After eight years' commitment in esports, we believe that sustained performance matters most and the cooling management is what decides it," said Bai Keke, Vice President of ZTE, "nubia Neo 5 GT Special Edition is designed to solve that challenge by combining active air-cooling, drawn from esports PC design, with active liquid-cooling, inspired by AI server thermal management. From the built-in fan we pioneered at MWC Barcelona 2026 to liquid cooling today, we're building a thermal-first ecosystem where young gamers can stay cool, stay smooth from start to finish."

Enter a New Era of Cooling with the Revolutionary AquaCore Cooling System
At the center of this model is nubia's AquaCore Cooling System, which combines liquid cooling and air cooling in a dual-active thermal architecture. The liquid cooling system uses an AI Server-Grade Coolant built for long-term reliability. Powered by a piezoelectric micropump and a three-layer cooling film, it drives continuous coolant circulation in a clockwise flow thus to transfer heat more efficiently from core components to cooler areas. A transparent design reveals the movement of the coolant, adding a distinctive gaming aesthetic that turns the engineering into part of the device's identity.

The built-in active cooling fan works together with Through-Flow Duct Design to generate a high-speed airflow path that accelerates heat dissipation. As the liquid loop draws heat away from core components, the fan helps expel it more efficiently. To further strengthen cooling efficiency, nubia has expanded the total heat dissipation area to 33,652 mm², combining VC, graphite, and liquid cooling technologies into one ultra-large thermal architecture.

Console-Level Control for Comfortable, Responsive Gameplay
nubia has equipped the device with 550Hz Neo Triggers 5.0 paired with the 3049Hz Instant Touch Rate and Magic Touch 3.0 algorithm, achieving the industry-leading sub-5.5ms latency to deliver an instant touch response. It also features a completely flat back, the only one in its class, with refined rounded corners and a 90-degree charging cable for a more comfortable in-hand feel.

Powered by the Cold-Core Trinity with MediaTek Dimensity 7400 4nm chipset, up to 24GB Dynamic RAM and NeoTurbo Engine optimization, it's built to deliver high and stable frame rates. This device equips a 6,210mAh dual-cell battery, supported by 80W (45W PD for EU market) fast charging and Bypass Charging. It also supports 5% Extreme Mode, delivering up to 30 minutes of extra gaming.

Immersive Gaming Experience Enhanced by AI Copilot Demi
nubia Neo 5 GT Special Edition features a 6.8-inch 1.5K AMOLED display with a 144Hz refresh rate and 4,500nits local peak brightness, delivering vivid clarity in fast-moving titles across changing light conditions. Paired with stereo dual speakers with DTS:X^® Ultra and an X-axis linear motor, it creates a more immersive sensory experience.

Beyond hardware, nubia has integrated AI Copilot Demi 2.0 to complement the way users game and interact. Features such as Gaming Coach, Gaming Chatbot, and Demi Auto-Chat are designed to provide guidance, support communication, and help users stay focused without interrupting gameplay.

nubia Neo 5 GT Special Edition rolls out globally this July, starting in Southeast Asia. The device comes in Surge Black and Glacial Silver, and is available in 24GB (12GB+12GB) RAM with 256GB or 512GB of storage, backed by a five-year software update commitment, reinforcing nubia's dedication to long-term stability.

MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: [email protected]

SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA), supporting commercial manufacturing for a potential blockbuster autoimmune therapy.

The seven-day FDA inspection conducted by three inspectors covered MFG8's quality management system and drug substance manufacturing processes. Passing this inspection further reinforces WuXi Biologics' outstanding regulatory compliance track record and demonstrates the company's robust and reliable quality system, proven GMP execution excellence, and integrated capabilities to support reliable global commercial manufacturing.

MFG8 is an important part of WuXi Biologics' global manufacturing network. Equipped with twelve 4,000L single-use bioreactors, the facility leverages WuXi Biologics' distinctive "scale-out" strategy to offer flexible commercial manufacturing at scales ranging from 4,000L to 20,000L. In addition, MFG8 incorporates the latest practices in sustainable construction and applies state-of-the-art technologies, including digital platforms and the rooftop photovoltaic system, to advance carbon reduction, resource reuse, and recycling.

Dr. Chris Chen, CEO of WuXi Biologics, commented: "MFG8's successful FDA Pre-License Inspection pass is a strong testament to WuXi Biologics' commitment to global quality and compliance standards. This PLI pass reflects our sustained investment in a world-class quality system and our proven capability to support partners in advancing global commercial manufacturing. We are pleased to help bring this potential blockbuster autoimmune therapy to patients through our high-quality manufacturing capabilities. Moving forward, WuXi Biologics will continue to empower global partners with a reliable quality system and accelerate the delivery of innovative biologics to more patients worldwide."

WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry's rigorous quality standards. As of the end of 2025, it has successfully passed 46 regulatory inspections, including 22 conducted by the FDA and EMA, and secured 136 facility license approvals. The company also holds an industry-leading record, achieving a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics has passed more than 1,800 GMP quality audits by global clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 25 drug substance facilities and 18 drug product facilities within its global network. Its world-class quality and compliance capabilities underpin long-standing trust from clients worldwide.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide*.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

Contacts

Business
[email protected]

Media
[email protected]

• RoboSense recorded 719,200 units in LiDAR sales in H1 2026, up 169.6% year over year, with robotics LiDAR sales surging 510.4% to 282,600 units.
• In Q2 2026, RoboSense recorded 388,900 units in LiDAR sales, including 97,100 units from robotics segment and 291,800 units from ADAS segment.

SHENZHEN, China, July 9, 2026 /PRNewswire/ -- RoboSense (HKEX: 02498), a pioneering robotics company for the Physical AI era, announced its LiDAR sales volume for the first half of 2026, with total LiDAR sales reaching 719,200 units, up 169.6% year over year, including 282,600 units in the robotics segment, up 510.4% year over year, and 436,600 units in the ADAS segment, up 98.0% year over year. The strong performance was driven by RoboSense's full-stack proprietary chip technologies and continued growth across both its ADAS and robotics segments.

The momentum continued into the second quarter, with total LiDAR sales reaching 388,900 units. Of these, robotics LiDAR sales totaled 97,100 units, up 182.3% year over year, while ADAS LiDAR sales reached 291,800 units, up 135.7% year over year.

Backed by the industry-leading performance and mass-production maturity of its digital product portfolio, including the E1R and Airy series, RoboSense has enabled a broad range of robotics applications, including embodied AI and commercial cleaning robots. Today, RoboSense ranks No. 1 globally in LiDAR sales across the overall robotics market and multiple robotics segments.¹

In April 2026, RoboSense unveiled its EOCENE SPAD-SoC architecture together with its Phoenix and Peacock chipsets, further pushing the performance boundaries of digital perception products. Meanwhile, cumulative deliveries of E Platform-based fully solid-state digital LiDAR products have surpassed 300,000 units, setting a new industry benchmark for large-scale deployment.

With continued advancements in in-house chip, product development, and scalable mass-production capabilities, RoboSense is well positioned to support the next phase of Physical AI commercialization. The company will continue to provide a more reliable spatial intelligence perception foundation for robotics and accelerating the deployment of robots in the real world.

About RoboSense

RoboSense (HKEX: 02498) is a robotics company for the era of Physical AI. Based on its in-house optoelectronic chips and perception algorithms, and supported by its scaled mass production capabilities, RoboSense provides robots with core components and infrastructure, including LiDAR and Space Camera. Its products have been deployed at scale across more than ten applications areas, including smart vehicles, Robotaxi, robotic lawn mowers, autonomous logistics, embodied intelligence, and commercial cleaning robots. RoboSense serves more than 3,400 robotics clients worldwide and ranked No. 1 globally in robotics LiDAR market share in 2025.

SK Hynix's US ADR will debut on Friday (10th), and it is reportedly more than seven times oversubscribed.

SK Group Chairman Chey Tae-won will attend the Nasdaq listing celebration ceremony, where he and the company's management team will share SK Hynix's mid- to long-term development strategy, Yonhap News Agency reported.

Chey said earlier this year that the market still views SK Hynix as a company producing general-purpose memory chips, and hence the company's market cap has yet to reflect its value.

During Chey's US visit, he is also expected to meet senior executives from global tech giants including NVIDIA Corporation (NVDA.US) and Tesla, Inc. (TSLA.US).
~

AASTOCKS Financial News
Website: www.aastocks.com

CXMT (688825.SH), the world's fourth-largest DRAM manufacturer, has officially kicked off its STAR Market IPO issuance process. The company plans to publicly issue 6.688 billion shares before the exercise of the over-allotment option, representing approximately 10% of the company's total share capital after the offering.

The initial strategic placement will involve 3.344 billion shares, accounting for 50% of the offering size and approximately 43.48% of the total shares to be issued after full exercise of the over-allotment option.

CXMT is projected to begin IPO subscription next Thursday (16th). The IPO is set to raise at least RMB29.5 billion, marking a record-high fundraising size for a STAR Market IPO.

CXMT expects revenue for 1H to range from RMB110 billion to RMB120 billion, representing a YoY upsurge of 612.53-677.31%. Net profit attributable to the parent company is expected to range from RMB50 billion to RMB57 billion, surging 2,244.03-2,544.19% YoY.
~

AASTOCKS Financial News
Website: www.aastocks.com